ResMed Inc. vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? ResMed Inc. trades at $227.51 (market cap $31.78B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $48.51 (market cap $73.20B). The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is far larger — about 2.3× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.17% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 91 Days on average.
| RMD | VTIP | |
|---|---|---|
Market Cap | $31.78B | $73.20B |
Volume | 1,128,382 | 2,480,668 |
Sector | Health | — |
52-Week High | $277.88 | $50.46 |
52-Week Low | $182.82 | $48.38 |
Typical Hold Time | 51 Days | 91 Days |
Enterprise Value | $31.14B | — |
Dividend Yield | 1.17% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
VTIP trades at $48.46, up 0.08% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The ETF, focused on short-term inflation-protected securities, shows strong institutional interest, with firms like NewEdge Advisors increasing positions by 45.5% in Q2 2026 (SEC filing, September 2026). Recent news highlights its role in hedging inflation amid rising energy prices and Fed rate hikes.
The outlook for VTIP is supported by its inflation-hedging appeal in a high-rate environment, but risks include interest rate sensitivity and competition from other TIPS ETFs. Wall Street sentiment is cautious yet constructive, given its low-cost structure and short-duration focus, positioning it as a defensive allocation for investors seeking inflation protection without significant rate risk.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →